Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.
Astera Labs filer submitted a Form 144 for the resale of 281,250 shares of Common Stock, including securities acquired as RSUs on 02/15/25. The filing lists J.P. Morgan Securities LLC as broker-dealer.
The filing also discloses prior sales by the same holder: 94,971 shares sold on 02/17/2026 for $11,758,145.75.
Astera Labs, Inc. director Jack R. Lazar reported an open-market sale of 2,500 shares of Common Stock at $130.0000 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following this sale, Lazar directly holds 84,851 shares of Astera Labs Common Stock, so the transaction represents a small portion of his reported holdings and appears to be a routine, pre-planned disposition rather than a discretionary trade.
ALAB insider filing reports a planned resale of 2,500 RSUs and discloses a prior sale of 7,500 common shares on 03/05/2026 for $898,471.75. The Form 144 lists the RSUs as issuer-originated with an intended sale date of 02/15/2026.
Astera Labs, Inc. Chief Financial Officer Desmond Lynch filed an initial ownership report on Form 3. The filing shows he beneficially owns 0 shares of Astera Labs common stock directly following this reporting event. This is a routine disclosure of insider ownership required for company officers.
Astera Labs, Inc. director Jack R. Lazar reported selling a total of 7,500 shares of common stock in open-market transactions on March 5, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The weighted average sale prices ranged from about $117.64 to $123.50 per share across multiple trades. After these transactions, Lazar directly holds 87,351 shares of Astera Labs common stock.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported open-market sales of 10,000 shares of common stock on March 2, 2026. The transactions were carried out in multiple tranches at weighted average prices ranging from about $113.37 to $120.99 per share.
The filing notes that all sales occurred automatically under a pre-established Rule 10b5-1 trading plan adopted on May 29, 2025, which is designed to systematically execute trades over time. Following these sales, Mazzara directly owns 128,084 shares of Astera Labs common stock.
Astera Labs reports rapid expansion and a move to profitability, highlighting both opportunity and risk. Revenue grew from $115.8 million in 2023 to $396.3 million in 2024 and $852.5 million in 2025, while net income reached $219.1 million after prior-year losses. The company focuses on semiconductor-based connectivity for cloud and AI infrastructure, with products like Aries PCIe/CXL retimers, Taurus Ethernet modules, Leo CXL memory controllers, and Scorpio fabric switches, all tied together by its COSMOS software suite. Growth is heavily concentrated: in 2025, one end customer generated more than 70% of revenue and the top three end customers 86%. As of June 30, 2025, non‑affiliate common stock held a $13.2 billion market value at $90.42 per share, and 170,214,503 shares were outstanding on January 31, 2026. Management flags key risks including AI adoption uncertainty, reliance on TSMC and a small set of manufacturing partners, exposure to U.S.–China trade and export controls, cybersecurity threats, and intense competition from larger chipmakers.
Astera Labs, Inc. Chief Executive Officer Mohan Jitendra reported automatic sales of 94,971 shares of common stock on February 17, 2026. The filing states these shares were sold to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units under a pre-arranged “sell to cover” election, and it notes the transactions were not discretionary trades by the reporting person.
After these sales, Jitendra continues to hold 1,452,739 shares of common stock directly. The filing also reports additional indirect holdings through a living trust and several estate-planning trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.